Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview

被引：28

作者：

Rezaee, Haleh ^{[1
,2
]}

Pourkarim, Fariba ^{[2
]}

Pourtaghi-Anvarian, Samira ^{[2
]}

Entezari-Maleki, Taher ^{[2
]}

Asvadi-Kermani, Touraj ^{[3
]}

Nouri-Vaskeh, Masoud ^{[4
,5
]}

机构：

[1] Tabriz Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tabriz, Iran

[2] Tabriz Univ Med Sci, Fac Pharm, Dept Clin Pharm, Tabriz, Iran

[3] Tabriz Univ Med Sci, Fac Med, Dept Surg, Tabriz, Iran

[4] Tabriz Univ Med Sci, Immunol Res Ctr, Daneshgah St,POB 5166614766, Tabriz, Iran

[5] Universal Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Tehran, Iran

来源：

PHARMACOLOGY RESEARCH & PERSPECTIVES | 2021年 / 9卷 / 01期

关键词：

adverse reactions; chloroquine; COVID-19; drug-drug interaction; Kaletra; remdesivir; PLUS RIBAVIRIN TREATMENT; PHARMACOKINETIC INTERACTIONS; HEPATITIS-C; RHEUMATOID-ARTHRITIS; PROTEASE INHIBITORS; COINFECTED PATIENTS; HEALTHY-VOLUNTEERS; CHLOROQUINE; TOCILIZUMAB; METABOLISM;

D O I：

10.1002/prp2.705

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.

引用

下载

页数：18

共 50 条

[1] Drug-drug Interactions of Antithrombotic Medications During Treatment of COVID-19
Firat, Oguzhan
Kelleci Cakir, Burcu
Demirkan, Kutay
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 18 (01) : 1 - 2
[2] Drug-drug interactions between COVID-19 therapeutics and psychotropic medications
Cuomo, Alessandro
Barilla, Giovanni
Serafini, Gianluca
Aguglia, Andrea
Amerio, Andrea
Cattolico, Matteo
Carmellini, Pietro
Spiti, Alessandro
Fagiolini, Andrea
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (12) : 925 - 936
[3] Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19
Biswas, Mohitosh
Roy, Debendra Nath
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (11)
[4] Drug-drug interactions in patients with COVID-19
Reactions Weekly, 2020, 1831 (1) : 8 - 8
[5] Drug-drug Interaction between Psychotropic Medications and Medications Used in COVID-19: Comparison of Online Databases
Chatterjee, Surobhi
Kar, Sujita Kumar
Prakash, Aathira Jaya
Bansal, Teena
Singh, Garima
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2023, 21 (03) : 534 - 543
[6] Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients
Zhaoyan Chen
Fangyuan Tian
Ya Zeng
BMC Geriatrics, 23
[7] Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients
Chen, Zhaoyan
Tian, Fangyuan
Zeng, Ya
BMC GERIATRICS, 2023, 23 (01)
[8] Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study
Boppana, Ujwal
Leonard, Thomas S.
Jolayemi, Ayodeji
Ansari, Maliha I.
Salib, Andrew
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
[9] COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions
Back, David
Marzolini, Catia
Hodge, Catherine
Marra, Fiona
Boyle, Alison
Gibbons, Sara
Burger, David
Khoo, Saye
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (01) : 212 - 213
[10] Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs
Land, M. Hunter
MacNair, Laura
Thomas, Brian F.
Peters, Erica N.
Bonn-Miller, Marcel O.
CANNABIS AND CANNABINOID RESEARCH, 2020, 5 (04) : 340 - 343

← 1 2 3 4 5 →